Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $4.0 million.

  • Capricor Therapeutics' Share-based Compensation rose 9487.06% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 6527.48%. This contributed to the annual value of $9.8 million for FY2024, which is 3209.74% up from last year.
  • Per Capricor Therapeutics' latest filing, its Share-based Compensation stood at $4.0 million for Q3 2025, which was up 9487.06% from $3.6 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Share-based Compensation high stood at $5.5 million for Q1 2025, and its period low was $712299.0 during Q2 2021.
  • In the last 5 years, Capricor Therapeutics' Share-based Compensation had a median value of $1.7 million in 2023 and averaged $2.0 million.
  • Data for Capricor Therapeutics' Share-based Compensation shows a peak YoY increase of 16162.05% (in 2021) and a maximum YoY decrease of 112.86% (in 2021) over the last 5 years.
  • Over the past 5 years, Capricor Therapeutics' Share-based Compensation (Quarter) stood at $780150.0 in 2021, then surged by 47.18% to $1.1 million in 2022, then soared by 62.14% to $1.9 million in 2023, then grew by 23.31% to $2.3 million in 2024, then skyrocketed by 74.13% to $4.0 million in 2025.
  • Its Share-based Compensation was $4.0 million in Q3 2025, compared to $3.6 million in Q2 2025 and $5.5 million in Q1 2025.